Clinical EfficacyThe combination of lunresertib and camonsertib has shown significant clinical activity in gynecological cancers, achieving up to a 50% response rate.
Financial StrengthRepare's cash balance of $179.4MM is estimated to be sufficient to fund operations into the second half of 2026, providing a strong financial runway.
Strategic FocusRepare's strategic reprioritization to concentrate on clinical oncology programs, including a workforce reduction, underscores its commitment to advancing its most promising projects.